We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RXST market cap is 2.12B. The company's latest EPS is USD -1.3142 and P/E is -43.53.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 17.49M | 20.81M | 22.2M | 28.58M | 29.51M |
| Operating Income | -13.1M | -13.62M | -12.51M | -10.85M | -10.67M |
| Net Income | -13.21M | -13.8M | -12.42M | -9.18M | -9.1M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.24M | 14.68M | 22.59M | 49.01M | 89.08M |
| Operating Income | -46.59M | -35.41M | -52.79M | -63.32M | -50.09M |
| Net Income | 126.22M | 27.58M | -48.69M | -66.76M | -48.61M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 202.53M | 195.26M | 181.85M | 182.55M | 183.17M |
| Total Liabilities | 57.52M | 38.07M | 20.37M | 22.19M | 19.24M |
| Total Equity | 145.01M | 157.19M | 161.48M | 160.36M | 163.93M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 110.43M | 100.68M | 192.72M | 150.16M | 182.55M |
| Total Liabilities | 87.46M | 44.91M | 54.48M | 60.26M | 22.19M |
| Total Equity | -419.81M | -430.59M | 138.24M | 89.9M | 160.36M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.76M | -25.31M | -33.29M | -41.59M | -9.31M |
| Investing | -48.37M | -43.97M | -26.7M | -22.13M | 24.27M |
| Financing | 65.31M | 66.2M | 57.96M | 61.52M | 7.99M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -40.62M | -35.2M | -44.71M | -58.85M | -41.59M |
| Investing | -5.87M | 15.59M | -81.91M | 39.95M | -22.13M |
| Financing | 1.33M | 25.24M | 137.34M | 6.33M | 61.52M |
| Market Cap | 2.12B |
| Price to Earnings Ratio | -43.53 |
| Price to Sales Ratio | 23.76 |
| Price to Cash Ratio | 218.36 |
| Price to Book Ratio | 13.2 |
| Dividend Yield | - |
| Shares Outstanding | 36.99M |
| Average Volume (1 week) | 383.33k |
| Average Volume (1 Month) | 355.44k |
| 52 Week Change | 117.81% |
| 52 Week High | 67.60 |
| 52 Week Low | 20.66 |
| Spread (Intraday) | 0.92 (1.6%) |
| Company Name | RxSight Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.rxsight.com |
| Industry | ophthalmic goods (3851) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
